Navigation Links
Acidic tumor pH inhibits drug effect
Date:2/11/2014

Low pH in tumours counteracts the desired effect of the drug chloroquine, according to a new study from Karolinska Institutet in Sweden. The results, which are published in the journal Autophagy, might explain possible lack of efficacy of chloroquine in clinical studies.

Chloroquine, a widely used antimalaria drug, is currently under investigation in clinical trials on cancer patients. It is the ability of chloroquine to inhibit autophagy in tumour cells that has piqued researchers' interest. Autophagy is a homeostatic process by which cells eat parts of themselves, so that damaged or unnecessary organelles and toxic proteins are broken down and recycled. In the absence of nutrients, cells resort to autophagy to survive. This way, autophagy helps cancer cells survive in tumour regions that are poor in nutrients and characterised by low oxygen and acidic pH.

Also, tumour cells use autophagy to protect themselves from many forms of anticancer therapies, including chemotherapy. Several studies have shown that inhibition of autophagy often increases chemosensitivity and radiosensitivity in tumour cells. Chloroquine combined with existing cancer treatment is thus considered to be a promising strategy. However, in some cancer models chloroquine seems to be unable to block autophagy, but the underlying mechanisms have not yet been identified.

In the present study, the scientists studied the effect of chloroquine in different cancer cells that were either cultured in acidic pH for a short time or adapted to chronic acidosis. The researchers also studied the effect in tumours grown in mice.

We discovered that a major consequence of the altered metabolism of tumour cells, the tissue acidification, is responsible for the lack of chloroquine anti-autophagic activity. The results suggest that chloroquine might lack efficacy in patients whose tumours are characterised by acidic regions, says Angelo De Milito at the Departmen
'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Corals could survive a more acidic ocean
2. Cystic fibrosis makes airways more acidic, reduces bacterial killing
3. Glimpse into the future of acidic oceans shows ecosystems transformed
4. New studies needed to predict how marine organisms may adapt to the futures acidic oceans
5. The loss of a protein makes jump the tumor to the lymph node
6. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
7. Dental X-rays linked to common brain tumor
8. TGen leads new National Institutes of Health study of brain tumors
9. Immune-response genes affecting breast tumor eradication
10. A single stem cell mutation triggers fibroid tumors
11. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Acidic tumor pH inhibits drug effect
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ... new funding to expand its team and bring LaunchKey ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... you are overweight and pregnant, your baby isn,t destined to ... research report published online in The FASEB Journal ... show that modifying fat intake during pregnancy to a moderate ... mother,s size. Specifically, they found that a protein called "SIRT1" ...
... This release is available in Spanish . ... United States as a source of sugar for syrup and ... make it uniquely suited to production as a bioenergy crop, ... an ideal candidate because of its drought tolerance, adaptability to ...
... industry are excellent sources of proteins and healthy oils ... moment these side streams are mainly used as fish ... waste. Coordinated by VTT, the APROPOS (Added value ... project seeks to enrich several co-stream components at once ...
Cached Biology News:Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2Sorghum eyed as a southern bioenergy crop 2Food industry's high-quality co-streams used effectively as raw material for new products 2
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... hold its 2015 Annual Meeting of Stockholders on May ... expected date for the Annual Meeting represents a change ...
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Wis. - Its not news that Wisconsin trails national ... whys of it are broken down and detailed in ... Venture Capital published by NorthStar Economics, Inc. The ... capital for Wisconsin companies. , ,The Wisconsin Technology Network ...
... Bays Nsight Telservices (www.nsighttel.com) in 2001 as Vice President ... as Chief Technical Officer (CTO) of Chicago startup BidBuyBuild. ... NET Cable, and NetNet and heads up the company's ... deployment. , , WTN: How did your dot-com ...
... more difficult challenges in business is turning around a sick ... the company is forced into bankruptcy. Realizing the painful reality ... impossible for owners and senior executives to deal with truthfully. ... them, and they will close that big outstanding proposal, and ...
Cached Biology Technology:Growing Venture Capital in Wisconsin 2Growing Venture Capital in Wisconsin 3Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 2Interview: WTN Gets Real with Appletons Brad Hansen - Dot-Com Experience helps Executive to Spot Trends 3Turning Around a Sick Company 2
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: